Details of the Drug

General Information of Drug (ID: DMNFUZR)

Drug Name

Enalapril

Synonyms

Vasotec; Enalapril (INN); Enalapril (TN); N-{(1S)-1-[(ethyloxy)carbonyl]-3-phenylpropyl}-L-alanyl-L-proline; N-[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]-L-alanyl-L-proline; (2S)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]pyrrolidine-2-carboxylic acid

Indication

Disease Entry	ICD 11	Status	REF
Congestive heart failure	BD10	Approved	[1]
Hypertension	BA00-BA04	Approved	[2]
Malignant essential hypertension	BA00	Approved	[1]
------------------------------------------------------------------------------------

Therapeutic Class

Antihypertensive Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

376.4

Logarithm of the Partition Coefficient (xlogp)

-0.1

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption Tmax: The time to maximum plasma concentration (Tmax) is 4 h [3]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Bioavailability: 63.5% of drug becomes completely available to its intended biological destination(s) [5]
Clearance: The renal clearance of drug is 158 +/- 47 mL/min [6]
Elimination: Enalapril is mainly eliminated through renal excretion, where approximately 94% of the total dose is excreted via urine or feces as either enalaprilat or unchanged parent compound [7]
Half-life: The concentration or amount of drug in body reduced by one-half in 35 - 38 hours [3]
Metabolism: The drug is metabolized via the de-esterification mediated by hepatic esterases [3]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 1.77178 micromolar/kg/day [8]
Water Solubility: The ability of drug to dissolve in water is measured as 25 mg/mL [4]

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Cough	Not Available	BDKRB2	OTOA9D3W	[9]
Hepatotoxicity	Not Available	CYP3A4	OTQGYY83	[9]
-----------

Chemical Identifiers

Formula: C20H28N2O5
IUPAC Name: (2S)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]pyrrolidine-2-carboxylic acid
Canonical SMILES: CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CCC[C@H]2C(=O)O
InChI: InChI=1S/C20H28N2O5/c1-3-27-20(26)16(12-11-15-8-5-4-6-9-15)21-14(2)18(23)22-13-7-10-17(22)19(24)25/h4-6,8-9,14,16-17,21H,3,7,10-13H2,1-2H3,(H,24,25)/t14-,16-,17-/m0/s1
InChIKey: GBXSMTUPTTWBMN-XIRDDKMYSA-N

Cross-matching ID

PubChem CID: 5388962
ChEBI ID: CHEBI:4784
CAS Number: 75847-73-3
DrugBank ID: DB00584
TTD ID: D00SEB
VARIDT ID: DR00010
INTEDE ID: DR0573
ACDINA ID: D00229

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Angiotensin-converting enzyme (ACE)	TTL69WB	ACE_HUMAN	Inhibitor	[10]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Peptide transporter 2 (SLC15A2)	DT8QKNP	S15A2_HUMAN	Substrate	[11]
Peptide transporter 1 (SLC15A1)	DT9G7XN	S15A1_HUMAN	Substrate	[12]
Multidrug resistance-associated protein 2 (ABCC2)	DTFI42L	MRP2_HUMAN	Substrate	[13]
Organic anion transporting polypeptide 1A2 (SLCO1A2)	DTE2B1D	SO1A2_HUMAN	Substrate	[14]
Organic anion transporting polypeptide 1B1 (SLCO1B1)	DT3D8F0	SO1B1_HUMAN	Substrate	[15]
Organic anion transporting polypeptide 1B3 (SLCO1B3)	DT9C1TS	SO1B3_HUMAN	Substrate	[13]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[16]
Carboxylesterase 1 (CES1)	DEB30C5	EST1_HUMAN	Substrate	[17]
Dipeptidase (pepV)	DEQMBHW	Q84BU9_LACLH	Substrate	[18]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Angiogenin (ANG)	OT3ECS6P	ANGI_HUMAN	Gene/Protein Processing	[19]
Angiotensinogen (AGT)	OTBZLYR3	ANGT_HUMAN	Gene/Protein Processing	[20]
ATP-binding cassette sub-family C member 4 (ABCC4)	OTO27PAL	MRP4_HUMAN	Regulation of Drug Effects	[21]
B2 bradykinin receptor (BDKRB2)	OTOA9D3W	BKRB2_HUMAN	Drug Response	[9]
Carbonic anhydrase 2 (CA2)	OTJRMUAG	CAH2_HUMAN	Gene/Protein Processing	[22]
Cytochrome P450 3A4 (CYP3A4)	OTQGYY83	CP3A4_HUMAN	Drug Response	[9]
Erythropoietin (EPO)	OTZ90CN4	EPO_HUMAN	Gene/Protein Processing	[20]
Interleukin-6 (IL6)	OTUOSCCU	IL6_HUMAN	Drug Response	[23]
Natriuretic peptides A (NPPA)	OTMQNTNX	ANF_HUMAN	Gene/Protein Processing	[24]
Renin (REN)	OT52GZR2	RENI_HUMAN	Gene/Protein Processing	[25]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Congestive heart failure

ICD Disease Classification

BD10

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Angiotensin-converting enzyme (ACE)	DTT	SLC33A1	2.62E-01	-0.01	-0.06
Multidrug resistance-associated protein 2 (ABCC2)	DTP	MRP2	1.85E-02	5.14E-02	3.36E-01
Organic anion transporting polypeptide 1A2 (SLCO1A2)	DTP	OATP1A2	2.28E-01	-5.92E-02	-1.22E-01
Peptide transporter 1 (SLC15A1)	DTP	PEPT1	6.91E-01	8.30E-03	7.24E-02
Organic anion transporting polypeptide 1B3 (SLCO1B3)	DTP	OATP1B3	3.85E-03	1.01E-01	7.72E-01
Peptide transporter 2 (SLC15A2)	DTP	PEPT2	8.33E-02	-3.63E-02	-1.27E-01
Organic anion transporting polypeptide 1B1 (SLCO1B1)	DTP	OATP1B1	8.47E-01	1.14E-02	8.20E-02
Carboxylesterase 1 (CES1)	DME	CES1	1.24E-01	1.06E-01	4.92E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	6.06E-01	-2.42E-02	-1.64E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Enalapril

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Aliskiren	DM1BV7W	Major	Increased risk of hyperkalemia by the combination of Enalapril and Aliskiren.	Hypertension [BA00-BA04]	[26]
Losartan	DM72JXH	Major	Increased risk of hyperkalemia by the combination of Enalapril and Losartan.	Hypertension [BA00-BA04]	[27]
TAK-491	DMCF6SX	Major	Increased risk of hyperkalemia by the combination of Enalapril and TAK-491.	Hypertension [BA00-BA04]	[27]
Indapamide	DMGN1PW	Moderate	Additive hypotensive effects by the combination of Enalapril and Indapamide.	Hypertension [BA00-BA04]	[28]
Trichlormethiazide	DMHAQCO	Moderate	Additive hypotensive effects by the combination of Enalapril and Trichlormethiazide.	Hypertension [BA00-BA04]	[28]
Telmisartan	DMS3GX2	Major	Increased risk of hyperkalemia by the combination of Enalapril and Telmisartan.	Hypertension [BA00-BA04]	[27]
Irbesartan	DMTP1DC	Major	Increased risk of hyperkalemia by the combination of Enalapril and Irbesartan.	Hypertension [BA00-BA04]	[27]
-----------


⏷ Show the Full List of 7 DDI Information of This Drug

Coadministration of a Drug Treating the Disease Different from Enalapril (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Enalapril and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[29]
Sodium bicarbonate	DMMU6BJ	Minor	Decreased absorption of Enalapril due to altered gastric pH caused by Sodium bicarbonate.	Acidosis [5C73]	[30]
Repaglinide	DM5SXUV	Moderate	Increased risk of hypoglycemia by the combination of Enalapril and Repaglinide.	Acute diabete complication [5A2Y]	[31]
Glibenclamide	DM8JXPZ	Moderate	Increased risk of hypoglycemia by the combination of Enalapril and Glibenclamide.	Acute diabete complication [5A2Y]	[31]
Tolazamide	DMIHRNA	Moderate	Increased risk of hypoglycemia by the combination of Enalapril and Tolazamide.	Acute diabete complication [5A2Y]	[31]
Insulin-glulisine	DMQI0FU	Moderate	Increased risk of hypoglycemia by the combination of Enalapril and Insulin-glulisine.	Acute diabete complication [5A2Y]	[31]
Insulin-aspart	DMX7V28	Moderate	Increased risk of hypoglycemia by the combination of Enalapril and Insulin-aspart.	Acute diabete complication [5A2Y]	[32]
Glipizide	DMZA5PQ	Moderate	Increased risk of hypoglycemia by the combination of Enalapril and Glipizide.	Acute diabete complication [5A2Y]	[31]
Nifedipine	DMSVOZT	Minor	Additive hypotensive effects by the combination of Enalapril and Nifedipine.	Angina pectoris [BA40]	[33]
Bedaquiline	DM3906J	Moderate	Increased risk of hepatotoxicity by the combination of Enalapril and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[34]
Linezolid	DMGFPU2	Moderate	Additive hypotensive effects by the combination of Enalapril and Linezolid.	Bacterial infection [1A00-1C4Z]	[35]
Cariprazine	DMJYDVK	Moderate	Additive hypotensive effects by the combination of Enalapril and Cariprazine.	Bipolar disorder [6A60]	[36]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Enalapril and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[37]
Mannitol	DMSCDY9	Moderate	Additive hypotensive effects by the combination of Enalapril and Mannitol.	Bronchiectasis [CA24]	[28]
Olopatadine	DMKMWQG	Moderate	Additive CNS depression effects by the combination of Enalapril and Olopatadine.	Conjunctiva disorder [9A60]	[38]
Drospirenone	DM1A9W3	Moderate	Increased risk of hyperkalemia by the combination of Enalapril and Drospirenone.	Contraceptive management [QA21]	[39]
Ardeparin	DMYRX8B	Moderate	Increased risk of hyperkalemia by the combination of Enalapril and Ardeparin.	Coronary thrombosis [BA43]	[27]
Selegiline	DM6034S	Moderate	Additive hypotensive effects by the combination of Enalapril and Selegiline.	Depression [6A70-6A7Z]	[35]
Isocarboxazid	DMAF1NB	Moderate	Additive hypotensive effects by the combination of Enalapril and Isocarboxazid.	Depression [6A70-6A7Z]	[35]
Tranylcypromine	DMGB5RE	Moderate	Additive hypotensive effects by the combination of Enalapril and Tranylcypromine.	Depression [6A70-6A7Z]	[35]
OPC-34712	DMHG57U	Moderate	Additive hypotensive effects by the combination of Enalapril and OPC-34712.	Depression [6A70-6A7Z]	[36]
Phenelzine	DMHIDUE	Moderate	Additive hypotensive effects by the combination of Enalapril and Phenelzine.	Depression [6A70-6A7Z]	[35]
Nitroglycerin	DMQ2491	Moderate	Additive hypotensive effects by the combination of Enalapril and Nitroglycerin.	Diabetic foot ulcer [BD54]	[40]
SODIUM CITRATE	DMHPD2Y	Minor	Decreased absorption of Enalapril due to altered gastric pH caused by SODIUM CITRATE.	Discovery agent [N.A.]	[30]
Ethacrynic acid	DM60QMR	Moderate	Additive hypotensive effects by the combination of Enalapril and Ethacrynic acid.	Essential hypertension [BA00]	[41]
Phenoxybenzamine	DM8KSQH	Moderate	Additive hypotensive effects by the combination of Enalapril and Phenoxybenzamine.	Essential hypertension [BA00]	[42]
Acetazolamide	DM1AF5U	Moderate	Additive hypotensive effects by the combination of Enalapril and Acetazolamide.	Glaucoma [9C61]	[28]
Methazolamide	DM7J2TA	Moderate	Additive hypotensive effects by the combination of Enalapril and Methazolamide.	Glaucoma [9C61]	[28]
Dichlorphenamide	DMH7IDQ	Moderate	Additive hypotensive effects by the combination of Enalapril and Dichlorphenamide.	Glaucoma [9C61]	[41]
Eplerenone	DMF0NQR	Moderate	Increased risk of hyperkalemia by the combination of Enalapril and Eplerenone.	Heart failure [BD10-BD1Z]	[43]
Furosemide	DMMQ8ZG	Moderate	Additive hypotensive effects by the combination of Enalapril and Furosemide.	Heart failure [BD10-BD1Z]	[28]
Amiloride	DMRTSGP	Major	Increased risk of hyperkalemia by the combination of Enalapril and Amiloride.	Heart failure [BD10-BD1Z]	[44]
Bumetanide	DMRV7H0	Moderate	Additive hypotensive effects by the combination of Enalapril and Bumetanide.	Heart failure [BD10-BD1Z]	[28]
Hydroflumethiazide	DMVPUQI	Moderate	Additive hypotensive effects by the combination of Enalapril and Hydroflumethiazide.	Heart failure [BD10-BD1Z]	[28]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Enalapril and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[45]
Efavirenz	DMC0GSJ	Moderate	Increased risk of hepatotoxicity by the combination of Enalapril and Efavirenz.	Human immunodeficiency virus disease [1C60-1C62]	[46]
Isosorbide mononitrate	DMYLMU0	Moderate	Additive hypotensive effects by the combination of Enalapril and Isosorbide mononitrate.	Hydrocephalus [8D64]	[40]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Enalapril and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[47]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Enalapril and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[48]
Potassium chloride	DMMTAJC	Major	Increased risk of hyperkalemia by the combination of Enalapril and Potassium chloride.	Hypo-kalaemia [5C77]	[49]
Propiomazine	DMKY8V1	Moderate	Additive hypotensive effects by the combination of Enalapril and Propiomazine.	Insomnia [7A00-7A0Z]	[36]
ITI-007	DMUQ1DO	Moderate	Additive hypotensive effects by the combination of Enalapril and ITI-007.	Insomnia [7A00-7A0Z]	[36]
Porfimer Sodium	DM7ZWNY	Moderate	Increased risk of photosensitivity reactions by the combination of Enalapril and Porfimer Sodium.	Lung cancer [2C25]	[50]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of hepatotoxicity by the combination of Enalapril and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[51]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Enalapril and Idelalisib.	Mature B-cell leukaemia [2A82]	[52]
Clofarabine	DMCVJ86	Moderate	Increased risk of hepatotoxicity by the combination of Enalapril and Clofarabine.	Mature B-cell lymphoma [2A85]	[53]
Lanthanum carbonate	DMMJQSH	Moderate	Decreased absorption of Enalapril due to formation of complexes caused by Lanthanum carbonate.	Mineral absorption/transport disorder [5C64]	[54]
Promethazine	DM6I5GR	Moderate	Additive hypotensive effects by the combination of Enalapril and Promethazine.	Nausea/vomiting [MD90]	[36]
Polythiazide	DMCH80F	Moderate	Additive hypotensive effects by the combination of Enalapril and Polythiazide.	Oedema [MG29]	[28]
Safinamide	DM0YWJC	Moderate	Additive hypotensive effects by the combination of Enalapril and Safinamide.	Parkinsonism [8A00]	[35]
Rasagiline	DM3WKQ4	Moderate	Additive hypotensive effects by the combination of Enalapril and Rasagiline.	Parkinsonism [8A00]	[35]
Terazosin	DM3JCVS	Moderate	Additive hypotensive effects by the combination of Enalapril and Terazosin.	Prostate hyperplasia [GA90]	[42]
Silodosin	DMJSBT6	Moderate	Additive hypotensive effects by the combination of Enalapril and Silodosin.	Prostate hyperplasia [GA90]	[42]
Levomepromazine	DMIKFEL	Moderate	Additive hypotensive effects by the combination of Enalapril and Levomepromazine.	Psychotic disorder [6A20-6A25]	[36]
Fluphenazine	DMIT8LX	Moderate	Additive hypotensive effects by the combination of Enalapril and Fluphenazine.	Psychotic disorder [6A20-6A25]	[36]
Leflunomide	DMR8ONJ	Major	Increased risk of hepatotoxicity by the combination of Enalapril and Leflunomide.	Rheumatoid arthritis [FA20]	[54]
Quetiapine	DM1N62C	Moderate	Additive hypotensive effects by the combination of Enalapril and Quetiapine.	Schizophrenia [6A20]	[36]
Mesoridazine	DM2ZGAN	Moderate	Additive hypotensive effects by the combination of Enalapril and Mesoridazine.	Schizophrenia [6A20]	[36]
Thioridazine	DM35M8J	Moderate	Additive hypotensive effects by the combination of Enalapril and Thioridazine.	Schizophrenia [6A20]	[36]
Aripiprazole	DM3NUMH	Moderate	Additive hypotensive effects by the combination of Enalapril and Aripiprazole.	Schizophrenia [6A20]	[36]
Iloperidone	DM6AUFY	Moderate	Additive hypotensive effects by the combination of Enalapril and Iloperidone.	Schizophrenia [6A20]	[36]
Paliperidone	DM7NPJS	Moderate	Additive hypotensive effects by the combination of Enalapril and Paliperidone.	Schizophrenia [6A20]	[36]
Molindone	DMAH70G	Moderate	Additive hypotensive effects by the combination of Enalapril and Molindone.	Schizophrenia [6A20]	[36]
Thiothixene	DMDINC4	Moderate	Additive hypotensive effects by the combination of Enalapril and Thiothixene.	Schizophrenia [6A20]	[36]
Trifluoperazine	DMKBYWI	Moderate	Additive hypotensive effects by the combination of Enalapril and Trifluoperazine.	Schizophrenia [6A20]	[36]
Risperidone	DMN6DXL	Moderate	Additive hypotensive effects by the combination of Enalapril and Risperidone.	Schizophrenia [6A20]	[36]
Amisulpride	DMSJVAM	Moderate	Additive hypotensive effects by the combination of Enalapril and Amisulpride.	Schizophrenia [6A20]	[36]
Asenapine	DMSQZE2	Moderate	Additive hypotensive effects by the combination of Enalapril and Asenapine.	Schizophrenia [6A20]	[36]
Trabectedin	DMG3Y89	Moderate	Increased risk of hepatotoxicity by the combination of Enalapril and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[55]
Tacrolimus	DMZ7XNQ	Moderate	Increased risk of hyperkalemia by the combination of Enalapril and Tacrolimus.	Transplant rejection [NE84]	[56]
Tolbutamide	DM02AWV	Moderate	Increased risk of hypoglycemia by the combination of Enalapril and Tolbutamide.	Type 2 diabetes mellitus [5A11]	[31]
Chlorpropamide	DMPHZQE	Moderate	Increased risk of hypoglycemia by the combination of Enalapril and Chlorpropamide.	Type 2 diabetes mellitus [5A11]	[31]
Insulin-detemir	DMOA4VW	Moderate	Increased risk of hypoglycemia by the combination of Enalapril and Insulin-detemir.	Type-1/2 diabete [5A10-5A11]	[31]
Insulin degludec	DMPL395	Moderate	Increased risk of hypoglycemia by the combination of Enalapril and Insulin degludec.	Type-1/2 diabete [5A10-5A11]	[31]
Methdilazine	DMAUHQX	Moderate	Additive hypotensive effects by the combination of Enalapril and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[36]
Trimeprazine	DMEMV9D	Moderate	Additive hypotensive effects by the combination of Enalapril and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[57]
-----------


⏷ Show the Full List of 76 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
D&C red no. 27	E00381	83511	Colorant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Maleic acid	E00418	444266	Acidulant; Buffering agent
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sodium stearate	E00453	2724691	Emulsifying agent; Gelling agent; Glidant; Modified-release agent; Stiffening agent; lubricant
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Carmellose sodium	E00625	Not Available	Disintegrant
Crospovidone	E00626	Not Available	Disintegrant
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Ferrous oxide	E00241	14945	Colorant
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Potassium bicarbonate	E00425	516893	Alkalizing agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium bicarbonate	E00424	516892	Alkalizing agent; Diluent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Zinc stearate	E00209	11178	lubricant
--------------------


⏷ Show the Full List of 25 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Enalapril 10 mg tablet	10 mg	Oral Tablet	Oral
Enalapril 20 mg tablet	20 mg	Oral Tablet	Oral
Enalapril 2.5 mg tablet	2.5 mg	Oral Tablet	Oral
Enalapril 5 mg tablet	5 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Enalapril FDA Label
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6322).
3	Enalapril: a review of human pharmacology. Drugs. 1985;30 Suppl 1:13-24. doi: 10.2165/00003495-198500301-00004.
4	BDDCS applied to over 900 drugs
5	Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
6	Ulm EH, Hichens M, Gomez HJ, Till AE, Hand E, Vassil TC, Biollaz J, Brunner HR, Schelling JL: Enalapril maleate and a lysine analogue (MK-521): disposition in man. Br J Clin Pharmacol. 1982 Sep;14(3):357-62. doi: 10.1111/j.1365-2125.1982.tb01991.x.
7	Todd PA, Goa KL: Enalapril. A reappraisal of its pharmacology and therapeutic use in hypertension. Drugs. 1992 Mar;43(3):346-81. doi: 10.2165/00003495-199243030-00005.
8	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
9	ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
10	Determination of bezafibrate, methotrexate, cyclophosphamide, orlistat and enalapril in waste and surface waters using on-line solid-phase extracti... J Environ Monit. 2009 Apr;11(4):830-8.
11	Ethanol inhibits functional activity of the human intestinal dipeptide transporter hPepT1 expressed in Xenopus oocytes. Alcohol Clin Exp Res. 2008 May;32(5):777-84.
12	The intestinal H+/peptide symporter PEPT1: structure-affinity relationships. Eur J Pharm Sci. 2004 Jan;21(1):53-60.
13	Vectorial transport of enalapril by Oatp1a1/Mrp2 and OATP1B1 and OATP1B3/MRP2 in rat and human livers. J Pharmacol Exp Ther. 2006 Jul;318(1):395-402.
14	Uptake of enalapril and expression of organic anion transporting polypeptide 1 in zonal, isolated rat hepatocytes. Drug Metab Dispos. 2000 Jul;28(7):801-6.
15	The modified dipeptide, enalapril, an angiotensin-converting enzyme inhibitor, is transported by the rat liver organic anion transport protein. Hepatology. 1998 Nov;28(5):1341-6.
16	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
17	Absorption and cleavage of enalapril, a carboxyl ester prodrug, in the rat intestine: in vitro, in situ intestinal perfusion and portal vein cannulation models. Biopharm Drug Dispos. 2015 Sep;36(6):385-397.
18	Characterization and kinetic analysis of enzyme-substrate recognition by three recombinant lactococcal PepVs. Arch Biochem Biophys. 2006 Oct 15;454(2):137-45.
19	Effects of enalapril maleate on blood pressure, renin-angiotensin-aldosterone system, and peripheral sympathetic activity in essential hypertension. Clin Ther. 1987;9(4):390-9.
20	Worsening of anemia by angiotensin converting enzyme inhibitors and its prevention by antiestrogenic steroid in chronic hemodialysis patients. J Cardiovasc Pharmacol. 1989;13 Suppl 3:S27-30. doi: 10.1097/00005344-198900133-00007.
21	Multichannel liquid chromatography-tandem mass spectrometry cocktail method for comprehensive substrate characterization of multidrug resistance-associated protein 4 transporter. Pharm Res. 2007 Dec;24(12):2281-96.
22	Captopril/enalapril inhibit promiscuous esterase activity of carbonic anhydrase at micromolar concentrations: An initro study. Chem Biol Interact. 2017 Mar 1;265:24-35.
23	Effect of enalapril and losartan on cytokines in patients with stable angina pectoris awaiting coronary artery bypass grafting and their interaction with polymorphisms in the interleukin-6 gene. Am J Cardiol. 2004 Sep 1;94(5):564-9. doi: 10.1016/j.amjcard.2004.05.017.
24	The effect of early converting enzyme inhibition on neurohumoral activation in acute myocardial infarction. Int J Cardiol. 1993 Nov;42(1):37-45. doi: 10.1016/0167-5273(93)90100-u.
25	A nonpeptide, piperidine renin inhibitor provides renal and cardiac protection in double-transgenic mice expressing human renin and angiotensinogen genes. Cardiovasc Drugs Ther. 2008 Dec;22(6):469-78. doi: 10.1007/s10557-008-6131-x. Epub 2008 Aug 5.
26	Health Canada "Potential risks of cardiovascular and renal adverse events in patients with type 2 diabetes treated with aliskiren (RASILEZ) or aliskiren/hydrochlorothiazide (RASILEZ HCT)." .
27	Product Information. Diovan (valsartan). Novartis Pharmaceuticals, East Hanover, NJ.
28	Burnakis TG, Mioduch HJ "Combined therapy with captopril and potassium supplementation: a potential for hyperkalemia." Arch Intern Med 144 (1984): 2371-2. [PMID: 6391404]
29	Cerner Multum, Inc. "Australian Product Information.".
30	Mantyla R, Mannisto PT, Vuorela A, Sundberg S, Ottoila P "Impairment of captopril bioavailability by concomitant food and antacid intake." Int J Clin Pharmacol Ther Toxicol 22 (1984): 626-9. [PMID: 6389377]
31	Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
32	Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7. [PMID: 6411511]
33	DeQuattro V "Comparison of benazepril and other antihypertensive agents alone and in combination with the diuretic hydrochlorothiazide." Clin Cardiol 14 (1991): iv28-32. [PMID: 1893639]
34	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
35	Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
36	Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
37	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
38	Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
39	Product Information. Yasmin (drospirenone-ethinyl estradiol) Berlex Laboratories, Richmond, CA.
40	Katz RJ, Levy WS, Buff L, Wasserman AG "Prevention of nitrate tolerance with angiotension converting enzyme inhibitors." Circulation 83 (1991): 1271-7. [PMID: 1901528]
41	Murphy BF, Whitworth JA, Kincaid-Smith P "Renal insufficiency with combinations of angiotensin converting enzyme inhibitors and diuretics." Br Med J 288 (1984): 844-5. [PMID: 6322905]
42	Baba T, Tomiyama T, Takebe K "Enhancement by an ACE inhibitor of first-dose hypotension caused by an alpha-blocker." N Engl J Med 322 (1990): 1237. [PMID: 1970122]
43	Product Information. Inspra (eplerenone). Searle, Chicago, IL.
44	Jarman PR, Mather HM "Diabetes may be independent risk factor for hyperkalaemia." BMJ 327 (2003): 812. [PMID: 14525902]
45	Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
46	Elsharkawy AM, Schwab U, McCarron B, et al. "Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser." J Clin Virol 58 (2013): 331-3. [PMID: 23763943]
47	Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
48	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
49	Product Information. K-Dur (potassium chloride). Schering Laboratories, Kenilworth, NJ.
50	Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
51	Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
52	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
53	Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
54	Canadian Pharmacists Association.
55	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
56	Perazella MA "Drug-induced hyperkalemia: old culprits and new offenders." Am J Med 109 (2000): 307-14. [PMID: 10996582]
57	Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.